Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Current Assets (2016 - 2025)

Rein Therapeutics (RNTX) has disclosed Current Assets for 10 consecutive years, with $4.3 million as the latest value for Q4 2025.

  • Quarterly Current Assets fell 68.32% to $4.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.3 million through Dec 2025, down 68.32% year-over-year, with the annual reading at $4.3 million for FY2025, 68.32% down from the prior year.
  • Current Assets for Q4 2025 was $4.3 million at Rein Therapeutics, down from $5.2 million in the prior quarter.
  • The five-year high for Current Assets was $64.3 million in Q1 2021, with the low at $4.3 million in Q4 2025.
  • Average Current Assets over 5 years is $25.2 million, with a median of $18.5 million recorded in 2023.
  • The sharpest move saw Current Assets surged 369.96% in 2021, then tumbled 72.31% in 2025.
  • Over 5 years, Current Assets stood at $48.2 million in 2021, then tumbled by 54.6% to $21.9 million in 2022, then decreased by 16.49% to $18.3 million in 2023, then dropped by 25.23% to $13.7 million in 2024, then tumbled by 68.32% to $4.3 million in 2025.
  • According to Business Quant data, Current Assets over the past three periods came in at $4.3 million, $5.2 million, and $6.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.